vimarsana.com

Page 34 - Dupilumab Development Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease

/PRNewswire/ Pivotal trial met primary and all key secondary endpoints Dupixent significantly reduced itch at 12 weeks, and nearly three times as many.

France generalUnited statesJohn reedGeorged yancopoulosRegeneron velocimmuneRegeneron pharmaceuticals incRegeneron genetics centerDupilumab development programRegeneron velocimmune technologyTeva pharmaceutical industries ltdExchange commissionGlobal head of researchChief scientific officerGlobal headWorst itch numeric rating scaleGlobal assessment

FDA Expands Approval of Dupixent® (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma

Press release content from PR Newswire. The AP news staff was not involved in its creation.

France generalGeorged yancopoulosNaimish patelRegeneron velocimmuneRegeneron pharmaceuticalsRegeneron pharmaceuticals incRegeneron genetics centerDrug administrationDupilumab development programRegeneron velocimmune technologyTeva pharmaceutical industries ltdExchange commissionHead of global development in immunologyEuropean unionChief scientific officerGlobal development

FDA Expands Approval of Dupixent® (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma

/PRNewswire/ Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting.

France generalGeorged yancopoulosNaimish patelRegeneron velocimmuneRegeneron pharmaceuticals incRegeneron genetics centerDrug administrationDupilumab development programRegeneron velocimmune technologyTeva pharmaceutical industries ltdExchange commissionHead of global development in immunologyEuropean unionChief scientific officerGlobal developmentAsthma control questionnaire

Investegate |Sanofi Announcements | Sanofi: FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma

Investegate announcements from Sanofi, FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma

United statesFrance generalEva schaefer jansenArnaud delepineFelix lauscherSharon chenGeorged yancopoulosVesna tosicNathalie phamSally bainNaimish patelRegeneron pharmaceuticals incRegeneron genetics centerDrug administrationDupilumab development programTeva pharmaceutical industries ltd

FDA Expands Approval of Dupixent® (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma

/PRNewswire/ Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting.

France generalGeorged yancopoulosNaimish patelRegeneron velocimmuneRegeneron pharmaceuticals incRegeneron genetics centerDrug administrationDupilumab development programRegeneron velocimmune technologyTeva pharmaceutical industries ltdExchange commissionHead of global development in immunologyEuropean unionChief scientific officerGlobal developmentAsthma control questionnaire

vimarsana © 2020. All Rights Reserved.